<DOC>
	<DOC>NCT00879983</DOC>
	<brief_summary>The purpose of this study is to estimate the pharmacokinetics and evaluate the safety following a single dose of azithromycin 2g extended-release powder for oral suspension with a 3-day dosing regimen of azithromycin 500mg tablet in Chinese healthy male subjects. This study data will be used to support azithromycin NDA in China.</brief_summary>
	<brief_title>An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Healthy volunteers. Male. 1845 years old. BMI 17.530.5 kg/m2. Alcohol, drug, smoke user. Sensitive to macrolide antibiotics class drug, parn or heparininduced thrombocytopenia. Severe medical or psychiatric condition or laboratory abnormality. Blood donation. 12ECG abnormal. Treatment with study drug; clinically significant.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>azithromycin, pharmacokinetics</keyword>
</DOC>